Annals of Nuclear Medicine

, 21:79 | Cite as

Reducing renal uptake of111In-DOTATOC: A comparison among various basic amino acids

  • Yung-Chang Lin
  • Guang-Uei Hung
  • Tsai-Yueh Luo
  • Shih-Chuan Tsai
  • Shung-Shung Sun
  • Chien-Chung Hsia
  • Shu-Ling Chen
  • Wan-Yu Lin
Technical Notes


Purpose: Several studies have reported significant renal toxicity after the use of a high dose of90Y-DOTATOC. Thus, renal protection is necessary in treatments with90Y-DOTA Tyr3-octroetide (DOTATOC). The infusion of certain positively charged amino acids has been shown to effectively reduce renal uptake of DOTATOC. In this study, we compared the effectiveness of three kinds of amino acids, D-lysine (lysine),L-arginine (arginine) and histidine, on renal protection in healthy rats and tried to determine which one was the most effective.Methods: Twenty SD healthy male rats were divided into 4 groups: lysine, histidine, arginine, and control. The rats were injected with a dose of 400 mg/kg of amono acid or 2 ml of phosphate-buffered saline (PBS) (as control) intraperitoneally. All rats were sacrificed at 4 hrs after the injection of 1 MBq111In-DOTATOC. Samples of the kidney were taken and weighed carefully. The counts of radioactivity were measured by a gamma counter and renal concentrations were calculated and expressed as percent injected dose per gram (% ID/g).Results: The renal uptake of111In-DOTATOC was significantly lower for all three kinds of amino acids when compared to the control group. The renal uptake of111In-DOTATOC in the lysine group was significantly lower than those in the histidine and arginine groups. The renal uptake of111In-DOTATOC in the histidine group was lower than that in the arginine group, but no statistical difference was noted.Conclusion: Among these three amino acids, lysine had the best reduction rate of renal uptake of DOTATOC. Histidine was more effective than arginine but no statistical difference was noted.

Key words

DOTATOC indium-111 lysine histidine arginine 


  1. 1.
    Hoyer D, Bell GI, Berelowitz M, Epelbaum J, Feniuk W, Humphrey PP, et al. Classification and nomenclature of somatostatin receptors.Trends Pharmacol Sci 1995; 16: 86–88.PubMedCrossRefGoogle Scholar
  2. 2.
    Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family.Life Sci 1995; 57: 1249–1265.PubMedCrossRefGoogle Scholar
  3. 3.
    Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, et al. Somatostatin-receptor scintigraphy with [111In-DTPA-D-Phel]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.Eur J Nucl Med 1993; 20: 716–731.PubMedCrossRefGoogle Scholar
  4. 4.
    Bakker WH, Albert R, Bruns C, Breeman WA, Hofland LJ, Marbach P, et al. [111In-DTPA-D-Phel]-octreotide, a potential radiopharmaceutical for imaging of somatostatin receptor-positive tumors: synthesis, radiolabeling andin vitro validation.Life Sci 1991; 49: 1583–1591.PubMedCrossRefGoogle Scholar
  5. 5.
    Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de-Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr3-octreotide.J Nucl Med 1992; 33: 652–658.PubMedGoogle Scholar
  6. 6.
    Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is deliveredin vivo to pancreatic, tumor cell, renal, and hepatocyte lysosomes.Cancer Res 1997; 57: 659–671.PubMedGoogle Scholar
  7. 7.
    McCarthy KE, Woltering EA, Anthony LB.In situ radiotherapy with111In-pentetreotide. State of the art and perspectives.Q J Nucl Med 2000; 44: 88–95.PubMedGoogle Scholar
  8. 8.
    Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical resutls.Eur J Nucl Med 1999; 26: 1439–1447.PubMedCrossRefGoogle Scholar
  9. 9.
    Otte A, Mueller-Brand J, Dellas S, Nitzsche EU, Herrmann R, Maecke HR. Yttrium-90-labelled somatostatin-analogue for cancer treatment.Lancet 1998; 351: 417–418.PubMedCrossRefGoogle Scholar
  10. 10.
    Cybulla M, Weiner SM, Otte A. End stage renal disease after treatment with90Y-DOTATOC.Eur J Nucl Med (2001; 28: 1552–1554.PubMedCrossRefGoogle Scholar
  11. 11.
    Paganelli G, Zoboli S, Cremonesi M, Bodei L, Ferrari M, Grana C, et al. Receptor-mediated radiotherapy with90Y-DOTA-d-Phe 1-Tyr3-octreotide.Eur J Nucl Med 2001; 28: 426–434.PubMedCrossRefGoogle Scholar
  12. 12.
    Bodei P, Cremonesi M, Soboli S, Grana C, Bartolomei M, Rocca P, et al. Receptor-mediated radionuclide therapy with90Y-DOTATOC in association with amino acid infusion: a phase 1 study.Eur J Nucl Med 2003; 30: 207–216.Google Scholar
  13. 13.
    Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 74. GBq (90)Y-DOTATOC.J Nuch Med 2002; 43: 610–616.Google Scholar
  14. 14.
    Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal throbotic microangiopathy: yttrium 90-DOTATOS internal radiotherapy.Am J Kidney Dis 2001; 37: 847–851.PubMedCrossRefGoogle Scholar
  15. 15.
    Behr TM, Sharkey RM, Juweid ME, Blumental RD, Dunn RM, Griffiths GL, et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives.Cancer Res 1995; 55: 3825–3834.PubMedGoogle Scholar
  16. 16.
    Hammond PJ, Wade AF, Gwilliam ME, PetersAM, Myers MJ, Gilbey SG, et al. Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue.Br J Cancer 1993; 67: 1437–1439.PubMedGoogle Scholar
  17. 17.
    Bernard BF, Krenning EP, Breeman WA, Rolleman EJ, Bakker WH, Visser TJ, et al.D-Lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake.J Nucl Med 1997; 38: 1929–1933.PubMedGoogle Scholar
  18. 18.
    Macke HR, Béhé M, Froidevaux S, Heppler A, Jermann E. DOTA-d-Phe(1)-Tyr(3)-octreotide (DOTATOC): a unique metallic radionuclides.J Nucl Med 1997; 38: 18P.Google Scholar
  19. 19.
    Otte A, Jermann E, Behe M, Bucher HC, Roser HW, et al. DOTATOC—a new powerful tool for receptormediated radionuclide therapy.Eur J Nucl Med 1997; 24: 792–795.PubMedGoogle Scholar
  20. 20.
    Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with111In-DOTATOS-Tyr3-octreotide: implications for internal radiotherapy with90Y-DOTATOC.Eur J Nucl Med 1999; 26: 877–886.PubMedCrossRefGoogle Scholar
  21. 21.
    Bodei L, Chinol M, Cremonesi M, Paganelli G. Facts and myths about radiopeptide therapy: Scylla, Charybdis and Sibyl.Eur J Nucl Med Mol Imaging 2002; 29: 1099–1100.PubMedCrossRefGoogle Scholar
  22. 22.
    de-Jong M, Rolleman EJ, Bernard BF, Visser TJ, Bakker WH, Breeman WA, et al. Inhibition of renal uptake of indium-111 DTPA-octreotidein vivo.J Nucl Med 1996; 37: 1388–1392.PubMedGoogle Scholar
  23. 23.
    Rolleman EJ, Valkema R, de-Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine.Eur J Nucl Med Mol Imaging 2003; 30: 9–15.PubMedCrossRefGoogle Scholar
  24. 24.
    de-Jong M, Bakker WH, Breeman WAP, Bernard BF, Hofland LJ, Visser TJ, et al. Pre-clinical comparison of [DTPA0] octreotide, [DTPA0, Tyr3] octreotide and [DOTA0, Tyr3] octreotide as carriers for somatostain receptor-targeted scintigraphy and radionuclide therapy.Int J Cancer 1998; 75: 406–411.PubMedCrossRefGoogle Scholar
  25. 25.
    Pimm MV, Gribben SJ. Prevention of renal tubule reabsorption of radiometal (indium-111) labeled fab fragment of a monoclonal antibody in mice by systemic administration of lysine.Eur J Nucl Med 1994; 21: 663–665.PubMedCrossRefGoogle Scholar
  26. 26.
    Akizawa H, Takimoto H, Saito M, Iwado A, Mifune M, Saito Y, et al. Effect of carboxylation ofN-terminal phenylalanine of111In-DTPA (diethylenetriaminepentaacetic acid)-oectreotide on accumulation of radioactivity in kidney.Biol Pharm Bull 2004; 27: 271–272.PubMedCrossRefGoogle Scholar
  27. 27.
    Behr TM, Behe M, Kluge G, Gotthardt M, Schipper ML, Gratz S, et al. Nephrotoxicity versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis.Eur J Nucl Med Mol Imaging 2002; 29: 277–279.PubMedCrossRefGoogle Scholar
  28. 28.
    Straathof JWA, Adamse M, Onkenhout W, Lamers CBHW, Masclee AAM. Effect ofl-arginine on lower esophageal sphincter motility in man.Eur J Gastroenterol Hepatol 2000; 12: 419–424.PubMedCrossRefGoogle Scholar
  29. 29.
    Kasaoka S, Tsuboyama-Kasaoka N, Kawahara Y, Inoue S, Tsuji M, Ezaki O, et al. Histidine supplementation suppresses food intake and fat accumulation in rats.Nutrition 2004; 20: 991–996.PubMedCrossRefGoogle Scholar
  30. 30.
    Rabbani GH, Sack DA, Ahmed S, Peterson JW, Saha SK, Marni F, et al. Antidiarrheal effects ofl-histidine supplemented rice-based oral rehydration solution in the treatment of male adults with severe cholera in Bangladesh: a doubleblind, randomized trial.J Infect Dis 2005; 191: 1507–1514.PubMedCrossRefGoogle Scholar

Copyright information

© Springer 2007

Authors and Affiliations

  • Yung-Chang Lin
    • 1
  • Guang-Uei Hung
    • 2
  • Tsai-Yueh Luo
    • 3
  • Shih-Chuan Tsai
    • 4
  • Shung-Shung Sun
    • 5
  • Chien-Chung Hsia
    • 3
  • Shu-Ling Chen
    • 3
  • Wan-Yu Lin
    • 4
    • 6
  1. 1.Department of Veterianry MedicineNational Chung-Hsing UniversityTaichungTaiwan
  2. 2.Department of Nuclear MedicineChanghua Christian HospitalChanghuaTaiwan
  3. 3.Isotope Application DivisionInstitute of Nuclear Energy ResearchTaoyuanTaiwan
  4. 4.Department of Nuclear MedicineTaichung Veterans General HospitalTaichungTaiwan
  5. 5.Department of Nuclear MedicineChina Medical College HospitalTaichungTaiwan
  6. 6.Institute of Medical TechnologyNational Chung-Hsing UniversityTaichungTaiwan

Personalised recommendations